貨號：DHD14201

產(chǎn)品鏈接：http://www.atagenix.com/product_detail-75559.html

產(chǎn)品購買聯(lián)系方式：027-65279366

產(chǎn)品介紹：Gatipotuzumab (PankoMab)是一種人源化單克隆抗體，可識別黏蛋白-1的腫瘤特異性表位 (TA-MUC1)。Gatipotuzumab具有有效的腫瘤特異性抗體依賴細胞毒性(ADCC)。

通用名:Gatipotuzumab

純度:>95% by SDS-PAGE.

濃度:1mg/ml

Formulationicon:0.01M PBS, pH 7.4.

內毒素:Please contact with the lab for this information.

別名:PankoMab, PankoMab-GEX, hPankoMab

靶點;物種:Human CD227/MUC1

種類:Humanized

受體鑒定:IgG1-kappa

CAS: 1264737-26-9

存儲條件：Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

Store at +4°C short term (1-2 weeks).

Store at -20 °C 12 months.

Store at -80°C long term.

參考文獻：

Potential Interplay of the Gatipotuzumab Epitope TA-MUC1 and Estrogen Receptors in Ovarian Cancer. PMID: 30642093

Maintenance therapy of patients with recurrent epithelial ovarian carcinoma with the anti-tumor-associated-mucin-1 antibody gatipotuzumab: results from a double-blind, placebo-controlled, randomized, phase II study. PMID: 34920291

Safety and preliminary activity results of the GATTO study, a phase Ib study combining the anti-TA-MUC1 antibody gatipotuzumab with the anti-EGFR tomuzotuximab in patients with refractory solid tumors. PMID: 35397434

Erratum to 'Safety and preliminary activity results of the GATTO study, a phase Ib study combining the anti-TA-MUC1 antibody Gatipotuzumab with the anti-EGFR Tomuzotuximab in patients with refractory solid tumors': [ESMO Open Volume 7, Issue 2, April 2022, 100447]. PMID: 35841804

TA-MUC1 as detected by the fully humanized, therapeutic antibody Gatipotzumab predicts poor prognosis in cervical cancer. PMID: 30062487

EP3 receptor is a prognostic factor in TA-MUC1-negative ovarian cancer. PMID: 31485769